Paris Descartes University

Viatris Appoints Corinne Le Goff as Chief Commercial Officer

Retrieved on: 
måndag, april 15, 2024
Corinne, Business administration, Viatris, Paris Descartes University, Senior, Patient, Pharming, Health, Biotechnology, COVID-19, Growth, Amgen, Management

PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today.

Key Points: 
  • PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today.
  • Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology company, where she led an organizational turnaround and rebranding effort.
  • Prior to Imunon, Le Goff served as Chief Commercial Officer at Moderna, where she was responsible for building the commercial organization and key capabilities necessary to ensure global access to Moderna's COVID-19 vaccine.
  • Le Goff said: "I am thrilled to join Viatris as the company embarks on its next exciting chapter.

Aitia Appoints Drug R&D Executive Jean-Michel Gries as President & Chief Operating Officer

Retrieved on: 
tisdag, september 19, 2023
Clinical pharmacology, Analytical chemistry, Drug development, Doctor of Pharmacy, University, Causal AI, Statistics, Roche, MBA, Parexel, Doctor of Philosophy, CNS, Science, Paris-Sud University, Wharton School of the University of Pennsylvania, Novartis, Patient, Ophthalmology, Widener University Commonwealth Law School, Drug discovery, Paris Descartes University, GNS, Digital twin, AI, Pharmacology, ChromeOS, Fine chemical, Alcon, Causality (physics)

SOMERVILLE, Mass., Sept. 19, 2023 /PRNewswire/ -- Aitia, the leader in the development and application of Causal AI and Digital Twins to discover and develop new drugs, today announced the appointment of Dr. Jean-Michel Gries as President & Chief Operating Officer.

Key Points: 
  • SOMERVILLE, Mass., Sept. 19, 2023 /PRNewswire/ -- Aitia, the leader in the development and application of Causal AI and Digital Twins to discover and develop new drugs, today announced the appointment of Dr. Jean-Michel Gries as President & Chief Operating Officer.
  • Jean-Michel is an accomplished senior life science executive with a track record of innovative drug discovery, translational medicine, and clinical development, combining the science and business of drug development.
  • He comes with a wealth of unique experience in drug R&D from big pharma, CROs, and small biotechs.
  • "I look forward to bringing my expertise and working alongside Colin and the teams towards revolutionizing drug discovery and development and ultimately improving the lives of patients."

Molecular Templates Announces Executive Leadership Changes

Retrieved on: 
onsdag, augusti 2, 2023
Columbia University, University, René, OSI Pharmaceuticals, Therapy, Senior, Transformation/transcription domain-associated protein, BioMarin Pharmaceutical, Wharton School of the University of Pennsylvania, Biotechnology, BeiGene, Medicine, Strategic planning, Washington University in St. Louis, Bachelor of Arts in Clinical Psychology, Business administration, Hematology, Paris Descartes University, ETB (company), Wesleyan University, Regulatory affairs, Master of Business Administration, Pharmacology, Mammography, ImClone Systems, Management, Nursing, Psychology, Neuroscience, Instituto de Biologia Molecular e Celular

AUSTIN, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced executive management changes to implement its next phase of development.

Key Points: 
  • AUSTIN, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced executive management changes to implement its next phase of development.
  • These appointments were made to better enable Molecular Templates to execute on its clinical and corporate objectives.
  • Dr. Grace Kim joined Molecular Templates in 2022 with 20 years of experience driving investor strategy, corporate strategy, and business development.
  • These management changes will help enable us to execute efficiently in the clinic and in our corporate goals,” said Eric Poma, PhD., Chief Executive and Chief Scientific Officer of Molecular Templates.

Versameb Strengthens its Board of Directors

Retrieved on: 
tisdag, juli 11, 2023
SPAC, Urinary incontinence, Faculty, Ferring Pharmaceuticals, Medical Affairs Bureau, Drug development, Pediatrics, University, Therapy, Gastroenterology, Ipsen, Roche, Infection, SUI, Faculty (division), MBA, RNA, Doctor of Philosophy, Faculty of Medical Sciences, University of Buenos Aires, Sarepta Therapeutics, M.D, Regeneration, Novartis, MD, European, CPA, CFO, Knowledge, Growth, Paris Diderot University, Obstetrics, IND, Paris Descartes University, Imperial College London, Brevan Howard, BLA, Medical device, Pharmaceutical industry, Management, Economics

The appointments come at a significant time of growth and expansion for Versameb.

Key Points: 
  • The appointments come at a significant time of growth and expansion for Versameb.
  • Dr Klaas Zuideveld, Chief Executive Officer of Versameb, said: "The experience of Hernán, Lily, Paul and Alexandre significantly strengthens the board of directors as we advance our lead candidate, VMB-100 for the treatment of SUI, into clinical development and further expand our technology platform, Versagile, with the development of two new discovery programs.
  • He is a member of the scientific advisory team for Laidlaw Venture Partners and serves on the Board of Directors for Voltron Therapeutics.
  • Versameb has developed a groundbreaking, proprietary technology platform, VERSagile, which optimizes the application of functional RNA in different disease contexts.

Versameb Strengthens its Board of Directors

Retrieved on: 
tisdag, juli 11, 2023
SPAC, Urinary incontinence, Faculty, Ferring Pharmaceuticals, Medical Affairs Bureau, Drug development, Pediatrics, University, Therapy, Gastroenterology, Ipsen, Roche, Infection, SUI, Faculty (division), MBA, RNA, Doctor of Philosophy, Faculty of Medical Sciences, University of Buenos Aires, Sarepta Therapeutics, M.D, Regeneration, Novartis, MD, European, CPA, CFO, Knowledge, Growth, Paris Diderot University, Obstetrics, IND, Paris Descartes University, Imperial College London, Brevan Howard, BLA, Medical device, Pharmaceutical industry, Management, Economics

The appointments come at a significant time of growth and expansion for Versameb.

Key Points: 
  • The appointments come at a significant time of growth and expansion for Versameb.
  • Dr Klaas Zuideveld, Chief Executive Officer of Versameb, said: "The experience of Hernán, Lily, Paul and Alexandre significantly strengthens the board of directors as we advance our lead candidate, VMB-100 for the treatment of SUI, into clinical development and further expand our technology platform, Versagile, with the development of two new discovery programs.
  • He is a member of the scientific advisory team for Laidlaw Venture Partners and serves on the Board of Directors for Voltron Therapeutics.
  • Versameb has developed a groundbreaking, proprietary technology platform, VERSagile, which optimizes the application of functional RNA in different disease contexts.

Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors

Retrieved on: 
måndag, maj 8, 2023
APRE, DNA, Drug development, Therapy, Pharmacia, DDR, Research, Mammography, Novartis, Patient, Maas, Cancer, Hematology, Paris Descartes University, Principal, Sanofi, Independent Board for Presbyterian Foreign Missions, Pharmaceutical industry, Aprea-Cuccaro clan, Pfizer

DOYLESTOWN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of Gabriela Gruia, M.D.

Key Points: 
  • DOYLESTOWN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of Gabriela Gruia, M.D.
  • to its Board of Directors, effective as of May 5, 2023.
  • Dr. Gruia joins Aprea with over 25 years of clinical, regulatory and life science leadership experience.
  • She also serves as an Independent Board Director at Tessa Therapeutics, TScan Therapeutics, and Molecular Templates.

Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments

Retrieved on: 
fredag, oktober 28, 2022
Company, LinkedIn, Heart failure, Growth, FRESH, CNRS, National Research Council Canada, Brain, Genomics, CEO, INSERM, III, Paris Descartes University, Patient, Euronext Growth, Cardiology, AHA, Research, GLOBE, Twitter, Medical research, Congress, Hypertension, Pharmaceutical industry

"Firibastat has unfortunately failed to demonstrate significantly greater efficacy than placebo in the phase III study FRESH.

Key Points: 
  • "Firibastat has unfortunately failed to demonstrate significantly greater efficacy than placebo in the phase III study FRESH.
  • This has caused the Company to prematurely discontinue the second phase III study, REFRESH, for ethical reasons concerning the patients.
  • For the same reason, in view of these results, it has been decided to stop the development of firibastat in cardiovascular," added Bruno Besse, Medical Director of Quantum Genomics.
  • Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain.

Bryan Garnier & Co Initiates the Coverage of Quantum Genomics with a Target Price at 13€ per Share

Retrieved on: 
torsdag, oktober 6, 2022
LinkedIn, Hypertension, Technology, FCA, Growth, Euronext Growth, Alliance for Heart Failure, Medical research, Patient, Research, Twitter, Oregon Department of Consumer and Business Services, FRESH, III, Consumer, INSERM, Heart failure, FINRA, American Heart Association, Paris Descartes University, OTCQX, Genomics, National Research Corporation, GLOBE, State, Brain, CNRS, Corporate services, Pharmaceutical industry, Health care

Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking founded in 1996.

Key Points: 
  • Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking founded in 1996.
  • It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services.
  • Quantum Genomics is a biopharmaceutical company specialising in the development of a new class of cardiovascular medications based on Brain Aminopeptidase A Inhibition (BAPAI).
  • Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain.

Quantum Genomics Announces That the Results Obtained with Firibastat in its Phase III Study, FRESH Will Now be Presented on November 7, 2022, During the AHA Conference in a Session Dedicated to Resistant Hypertension

Retrieved on: 
måndag, september 26, 2022
Safety, Paris Descartes University, Twitter, CNRS, Brain, Heart failure with preserved ejection fraction, LinkedIn, National Research Universal reactor, American Heart Association, Hypertension, Heart failure, INSERM, Patient, Euronext Growth, Growth, III, Medical research, AHA, Genomics, Research, GLOBE, Hospital, Public health, Pharmaceutical industry, FRESH

Once again this demonstrates the interest of the scientific community for this new therapeutic class, represented by firibastat, used to treat resistant hypertension."

Key Points: 
  • Once again this demonstrates the interest of the scientific community for this new therapeutic class, represented by firibastat, used to treat resistant hypertension."
  • The results of the FRESH study, presented at the AHA conference by Professor Bakris, will constitute a crucial first step towards the submission of a registration file to the American and European authorities.
  • The FRESH study is the first pivotal phase III study whose objective is to evaluate the efficacy and safety of firibastat in difficult-to-treat and resistant hypertension.
  • Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain.

One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program

Retrieved on: 
tisdag, september 13, 2022
Oncology, Health, Medical Devices, Stem Cells, Genetics, Other Health, Biotechnology, Therapy, Research institute, Trial of the century, Paris Descartes University, Algorithm, Institute, Transplant, Biomarker, Hospital, Coronavirus Scientific Advisory Board (Turkey), PIA, BPI, List of life sciences, Partnership, VCS, MD–PhD, Sofinnova, Patient, Program, Single-cell analysis, Cancer, Intelligence, CEO, Necker–Enfants Malades Hospital, Doctor of Philosophy, Saint Joseph Hospital, Barbados, AI, Larynx, Curie Institute (Paris), Medical device, Pharmaceutical industry, French Institute for Research in Computer Science and Automation

This new study aims at better understanding, with unprecedented granularity of information, the mechanisms involved in neoadjuvant chemotherapy response and resistance.

Key Points: 
  • This new study aims at better understanding, with unprecedented granularity of information, the mechanisms involved in neoadjuvant chemotherapy response and resistance.
  • One Biosciences will evaluate samples from patients enrolled at the Hartmann Clinic and Paris Saint-Joseph Hospital, in partnership with the Research Center of Institut Rafal (Institut Rafal Centre de Recherche).
  • One Biosciences has also benefited from BPI Frances support through non-dilutive grants (BFTE, PIA and Aide au Dveloppement DeepTech).
  • Dr. Magali Richard, co-founder of Home Biosciences and CEO of One Biosciences, said "We have assembled a unique discovery engine in a record timeframe.